Bart Neyns

31.1k total citations · 6 hit papers
316 papers, 13.9k citations indexed

About

Bart Neyns is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Bart Neyns has authored 316 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 215 papers in Oncology, 108 papers in Molecular Biology and 90 papers in Immunology. Recurrent topics in Bart Neyns's work include Cancer Immunotherapy and Biomarkers (118 papers), CAR-T cell therapy research (88 papers) and Immunotherapy and Immune Responses (75 papers). Bart Neyns is often cited by papers focused on Cancer Immunotherapy and Biomarkers (118 papers), CAR-T cell therapy research (88 papers) and Immunotherapy and Immune Responses (75 papers). Bart Neyns collaborates with scholars based in Belgium, United States and Netherlands. Bart Neyns's co-authors include Sofie Wilgenhof, Kris Thielemans, Eric Van Cutsem, Alain Hendlisz, Carlo Heirman, Jurgen Corthals, Jean‐Jacques Grob, Marc Peeters, Yves Humblet and Salvatore Siena and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bart Neyns

297 papers receiving 13.6k citations

Hit Papers

Open-Label Phase III Trial of Panitumumab Plus Best Suppo... 2007 2026 2013 2019 2007 2018 2009 2017 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
    2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
  2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
    2018 1.4k citations Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology profile →
  3. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    2009 934 citations Bart Neyns et al. profile →
  4. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Bart Neyns et al. profile →
  5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Bart Neyns et al. profile →
  6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bart Neyns Belgium 53 9.8k 4.4k 4.2k 2.6k 1.7k 316 13.9k
Douglas B. Johnson United States 59 9.8k 1.0× 4.0k 0.9× 4.6k 1.1× 2.4k 0.9× 839 0.5× 293 14.1k
Amita Patnaik United States 62 8.4k 0.9× 2.7k 0.6× 6.2k 1.5× 4.5k 1.7× 867 0.5× 365 14.4k
Igor Puzanov United States 59 10.2k 1.0× 3.9k 0.9× 6.8k 1.6× 3.2k 1.2× 735 0.4× 302 15.5k
Axel Hoos United States 55 9.2k 0.9× 4.7k 1.1× 3.4k 0.8× 2.8k 1.1× 535 0.3× 142 13.4k
Steven O’Day United States 52 9.5k 1.0× 4.6k 1.0× 4.7k 1.1× 2.4k 0.9× 705 0.4× 198 12.9k
Kim Margolin United States 63 11.0k 1.1× 5.5k 1.2× 6.5k 1.5× 5.6k 2.1× 1.2k 0.7× 312 17.9k
Aurélien Marabelle France 63 10.2k 1.0× 5.8k 1.3× 2.8k 0.6× 3.1k 1.2× 620 0.4× 281 15.2k
Alexander M. Menzies Australia 55 9.8k 1.0× 3.2k 0.7× 5.1k 1.2× 2.5k 0.9× 787 0.5× 330 12.6k
Matteo S. Carlino Australia 51 9.6k 1.0× 3.7k 0.9× 4.7k 1.1× 2.0k 0.8× 569 0.3× 303 12.5k
Harriet M. Kluger United States 59 7.7k 0.8× 3.5k 0.8× 5.1k 1.2× 3.1k 1.2× 823 0.5× 319 12.4k

Countries citing papers authored by Bart Neyns

Since Specialization
Citations

This map shows the geographic impact of Bart Neyns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Neyns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Neyns more than expected).

Fields of papers citing papers by Bart Neyns

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Neyns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Neyns. The network helps show where Bart Neyns may publish in the future.

Co-authorship network of co-authors of Bart Neyns

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Neyns. A scholar is included among the top collaborators of Bart Neyns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Neyns. Bart Neyns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Donia, Marco, Henrik Jespersen, Mathilde Jalving, et al.. (2025). Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open. 10(3). 104295–104295. 2 indexed citations
3.
Awada, Gil, et al.. (2024). Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report. Frontiers in Medicine. 11. 1436774–1436774. 1 indexed citations
4.
5.
6.
Wilgenhof, Sofie, et al.. (2023). Combination of regorafenib with BRAF-/MEK-inhibitors for the treatment of patients with refractory melanoma brain metastases.. Journal of Clinical Oncology. 41(16_suppl). e14003–e14003. 1 indexed citations
7.
Keyaerts, Marleen, et al.. (2022). Computer-aided detection and segmentation of malignant melanoma lesions on whole-body 18F-FDG PET/CT using an interpretable deep learning approach. Computer Methods and Programs in Biomedicine. 221. 106902–106902. 14 indexed citations
8.
Rogiers, Anne, Christophe Leys, Adrian Schembri, et al.. (2020). Neurocognitive Function, Psychosocial Outcome, and Health‐Related Quality of Life of the First‐Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of Immunology Research. 2020(1). 2192480–2192480. 31 indexed citations
9.
Overman, Michael J., Sara Lonardi, Ka Yeung Mark Wong, et al.. (2018). Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. Journal of Clinical Oncology. 36(8). 773–779. 1429 indexed citations breakdown →
10.
Wilgenhof, Sofie, Jurgen Corthals, Carlo Heirman, et al.. (2016). Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Journal of Clinical Oncology. 34(12). 1330–1338. 240 indexed citations
11.
Chevolet, Inès, Max Schreuer, Reinhart Speeckaert, et al.. (2015). Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients. Melanoma Research. 25(4). 357–361. 10 indexed citations
12.
Chevolet, Inès, Reinhart Speeckaert, Max Schreuer, et al.. (2015). Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. Journal of Translational Medicine. 13(1). 9–9. 52 indexed citations
13.
Four, Stephanie Du, Angela Hong, Matthew Chan, et al.. (2014). Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Reports in Oncological Medicine. 2014. 1–6. 33 indexed citations
14.
Grève, Jacques De, et al.. (2010). CLINICAL OUTCOME OF PATIENTS TREATED WITH HEPATIC ARTERIAL INFUSION OF OXALIPLATIN AND L-FOLINIC ACID MODULATED 5-FLUOROURACIL FOR INOPERABLE COLORECTAL CANCER LIVER METASTASES, A SINGLE CENTER EXPERIENCE. Annals of Oncology. 221–221. 1 indexed citations
15.
Stupp, Roger, Monika E. Hegi, Bart Neyns, et al.. (2010). Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(16). 2712–2718. 341 indexed citations
16.
Baren, Nicolas van, Aude Bonehill, Jurgen Corthals, et al.. (2009). Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. Melanoma Research. 19(6). 385–390. 3 indexed citations
17.
Cutsem, Eric Van, Salvatore Siena, Yves Humblet, et al.. (2007). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 19(1). 92–98. 128 indexed citations
18.
Siena, Salvatore, Yves Humblet, Eric Van Cutsem, et al.. (2006). Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial. Annals of Oncology. 17. 249–249. 2 indexed citations
19.
Neyns, Bart, Yves Van Nieuwenhove, Christel Fontaine, et al.. (2004). A feasibility study on hepatic arterial infusion (HAI) of oxaliplatin followed by I-folinic acid modulated continuous HAI of 5-fluorouracil as second line chemotherapy for stage IV colorectal cancer limited to the liver. Ghent University Academic Bibliography (Ghent University). 2 indexed citations
20.
Neyns, Bart, Ives Hubloue, K. Von Kemp, Kristin Jochmans, & Luc Huyghens. (1998). Unusual presentation of heparin induced thrombocytopenia in a patient with inherited activated protein C resistance.. Acta Clinica Belgica. 53. 293–294. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas B. Johnson Breakdown of academic impact, for papers by Amita Patnaik Breakdown of academic impact, for papers by Igor Puzanov Breakdown of academic impact, for papers by Axel Hoos Breakdown of academic impact, for papers by Steven O’Day Breakdown of academic impact, for papers by Kim Margolin Breakdown of academic impact, for papers by Aurélien Marabelle Breakdown of academic impact, for papers by Alexander M. Menzies Breakdown of academic impact, for papers by Matteo S. Carlino Breakdown of academic impact, for papers by Harriet M. Kluger
Rankless by CCL
2026